ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Gene Therapy

Passage Bio plans for IPO

by Ryan Cross
February 15, 2020 | APPEARED IN VOLUME 98, ISSUE 7

Passage Bio, a gene therapy firm founded by University of Pennsylvania scientist James Wilson, plans to raise $125 million in an initial public offering. Since formally launching in February 2019, Passage has raised over $225 million from private investors. The firm licensed its six preclinical gene therapies for rare central nervous system diseases from Penn and plans to begin clinical trials for three of them next year. Passage relies on Penn for its preclinical work and has an option to license six more gene therapies through 2022. Passage has already paid Penn more than $40 million, and Penn could earn up to $55 million for each program.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment